ArticleLife (Basel, Switzerland)2026
Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Actinic keratoses (AKs) are skin conditions that arise from the proliferation of atypical keratinocytes and are considered precursors to cutaneous squamous cell carcinoma. There are several treatment options available, which can be categorized into two main groups: lesion-directed therapies and field-directed therapies. Tirbanibulin 1% ointment has emerged as a new treatment for AKs. We conducted a meta-analysis to evaluate the effectiveness of tirbanibulin by analyzing the rates of complete clearance (CC) and partial clearance (PC) in randomized controlled trials (RCTs) and real-world studies. Our search included four databases: PubMed, Google Scholar, Scopus, and Web of Science. After applying specific inclusion and exclusion criteria, we identified 11 study cohorts from 10 publications. The CC rate was reported in 10 of the 11 studies, involving a total of 2092 patients, with 874 CC events observed. This resulted in an overall pooled CC rate of 52.05% (95% CI: 42.43-61.52%). The PC rate was also reported in 10 of the 11 studies, involving a total of 2367 patients, with 1631 PC events recorded. This led to an overall pooled PC rate of 71.96% (95% CI: 64.89-78.09%). In conclusion, tirbanibulin 1% ointment has shown clinical effectiveness and should be considered a promising treatment for AKs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.